Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD – The Liver Meeting® 2023 November 10, 2023 by Leave a Comment Last Updated on November 10, 2023 by [#item_full_content] Share this:TwitterFacebookMorePrintLike this:Like Loading... Related Spread the word
Leave a Reply